Abstract
SARS-CoV-2 infection in children results in a wide range of clinical outcomes. Paediatric Multisystem Inflammatory syndrome temporally associated with COVID-19(PIMS-TS) occurs weeks after a SARS-CoV-2 infection, and results in severe illness. This protocol describes a study to fully characterize the circulating proteome of children who have PIMS-TS, the proteome of healthy children who have previously been infected with SARS-CoV-2 and the proteome of febrile children with a confirmed invasive infection. Orthogonal proteomic techniques will be utilized to provide a deep proteomic characterization.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://bmjopen.bmj.com/content/10/11/e041661
https://adc.bmj.com/content/106/7/680
Funding Statement
This work was supported by HSC R&D Division, Public Health Agency Ref: COM/5596/20, Northern Ireland Chest Heart and Stroke 2021_H03, and the Dr Dinah Kohner Studentship. These funding sources had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit result.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval to conduct this study was provided by Belfast Health & Social Care Trust Research Governance (Reference 19147TW SW) and the London Chelsea Research ethics committee (REC Reference 20/HRA/1731).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# First author
Data Availability
All data produced in the present study are available upon reasonable request to the authors.